• EZ Cap™ Human p53 mRNA: Evidence Boundaries

  2026-10-14

  R1024 EZ Cap™ Human p53 mRNA (ψUTP) is documented by APExBIO as a research-use modified mRNA intended to encode human p53. The available information establishes product identity and intended molecular context, but provides no identity-matched study, product-specific readouts, delivery data, efficacy results, or safety evidence.

• Omeprazole: Identity and Evidence Scope

  2026-10-14

  The APExBIO catalog entry identifies SKU A2845 as Omeprazole and presents it as an H+,K+-ATPase inhibitor for gastric acid secretion research and related antiulcer studies. The supplied evidence is limited to product information: no matched primary paper or independent analytical record is available, so the listed identity, activity values, and intended research scope should be treated as supplier-reported claims rather than independently established findings.

• Trelagliptin, RUNX2, and Bone Formation

  2026-10-13

  A cell-based study reported that trelagliptin enhanced osteoblastic differentiation and mineralization in MC3T3-E1 cells, with findings consistent with involvement of RUNX2 and AMPK signaling. The evidence is mechanistic and preliminary: it does not establish benefit in human bone, osteoporosis, or fracture prevention. Red Blood Cell Lysis Buffer is a separate blood-sample preparation product and was not identified as part of the cited study.

• DHT, AR Signaling, and Resistance Evidence

  2026-10-13

  Dihydrotestosterone (DHT) is an androgen receptor agonist with documented relevance to androgen receptor signaling, but the supplied evidence does not show that DHT itself causes the ECM1–ENO1 mechanism reported in enzalutamide-resistant bone metastatic prostate cancer. The resistance study supports a tumor–bone microenvironment model, while the DHT-related claims are primarily product-described or model-specific and should not be generalized to patients.

• FAISL, FAK and TNBC: What the Study Shows

  2026-10-12

  A 2024 Advanced Science study proposes that the long noncoding RNA FAISL stabilizes focal adhesion kinase (FAK) by limiting Calpain 2-mediated proteolysis, thereby supporting triple-negative breast cancer progression and metastasis. The evidence combines tumor-dataset analysis, molecular interaction studies, cancer-cell phenotypes and mouse models, but remains preclinical and does not establish a clinical treatment strategy or a role for ionomycin.

• FAISL, FAK, and TNBC: What the Study Shows

  2026-10-12

  A source-grounded overview of a 2024 Advanced Science study linking the long noncoding RNA FAISL to FAK protein stability, Calpain 2-mediated proteolysis, and aggressive triple-negative breast cancer behavior. The available evidence supports a mechanistic model in cellular and mouse models, but does not establish clinical efficacy or connect the findings to ionomycin.

• Saracatinib and Reelin–SFK Evidence Gaps

  2026-10-11

  The published mouse study supports a permissive role for Reelin–Apoer2–Src-family-kinase signaling in ketamine-associated synaptic and behavioral effects, but it does not establish Saracatinib (AZD0530) as the compound responsible or demonstrate a human antidepressant application. The main evidence gap is the distance between pathway-level pharmacology and compound-specific, clinically applicable conclusions.

• Protease Inhibition in Cancer Research: Evidence and Limits

  2026-10-10

  A source-grounded overview of the DiscoveryProbe™ Protease Inhibitor Library, its conceptual uses in protease activity modulation, and how its research relevance compares with published findings on PSMD14, CARM1, and hepatocellular carcinoma.

• Eclipta–Hordeum Extract Delays Precocious Puberty

  2026-10-09

  A 2025 rat study found that an Eclipta prostrata–Hordeum vulgare extract complex delayed vaginal opening, reduced ovarian maturation, and attenuated hypothalamic GnRH mRNA elevation in Danazol- and high-fat-diet models of precocious puberty. The work is notable for testing the same botanical intervention across pharmacological and metabolic model contexts, while remaining preclinical and hypothesis-generating.

• Canagliflozin Hemihydrate: Beyond SGLT2

  2026-10-09

  Canagliflozin hemihydrate offers translational researchers a mechanism-defined way to study renal glucose reabsorption and glucose homeostasis without overclaiming mTOR activity. This article interprets recent yeast-screening evidence, outlines an evidence framework for metabolic studies, and distinguishes product provenance from biological validation.

• MAPK10–KRT16 Axis in NSCLC Metastasis

  2026-10-08

  A 2026 study identifies MAPK10 as a metastasis-suppressing kinase that phosphorylates KRT16, enabling RNF213-mediated ubiquitination and proteasomal degradation. Cellular, animal, and clinical evidence supports the MAPK10–KRT16–RNF213 axis as a mechanistic framework, while the limited clinical cohort and need for independent validation constrain immediate translational conclusions.

• Novel PRRSV-1 in Southern China: Genome and Pathogenicity

  2026-10-08

  Xu et al. report the isolation and characterization of GD2022, a PRRSV-1 strain identified in southern China, combining cell-based recovery, molecular confirmation, genome-wide analysis, and piglet pathogenicity assessment. The study strengthens surveillance evidence for PRRSV-1 diversity in China while showing why a single isolate should not be treated as a population-wide or vaccine-performance conclusion.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-10-07

  Breen and colleagues developed a genetically drug-sensitized yeast platform that improves detection of compounds affecting the TOR pathway while distinguishing rapamycin-dependent mechanisms from broader TOR inhibition. The study identified strong sensitivity gains for benchmark inhibitors, detected an otherwise obscure AZD8055 response, and found no evidence that canagliflozin inhibited TOR in this model.

• Osteoblast ECM1 and Anti-Androgen Resistance

  2026-10-07

  Wang and colleagues identify a bone-microenvironment mechanism in which enzalutamide-treated osteoblasts increase ECM1 secretion, enabling prostate cancer cells to resist anti-androgen therapy through an ENO1–GRB2–SOS1–MAPK axis. The study shifts attention from tumor-intrinsic resistance alone toward stromal signals and supports ECM1 and ENO1 as candidate intervention points, while remaining preclinical and mechanistically bounded.

• ATP as a Translational Signal in Immunogenic Cell Death

  2026-10-06

  ATP is more than a metabolic currency in oncology research: in immunogenic cell death, extracellular ATP can function as a damage-associated signal that links tumor-cell injury to immune activation. This article interprets findings from a 2026 colorectal cancer study and explains how a Luminescent ATP Detection Assay Kit can contribute to a broader, evidence-aware translational strategy without treating ATP as a standalone surrogate for immune efficacy.

8568 records 1/572 page Next 12345 下5页 Last page